Cargando…

Newer Antibacterials in Therapy and Clinical Trials

In order to deal with the rising problem of antibiotic resistance, newer antibacterials are being discovered and added to existing pool. Since the year 2000, however, only four new classes of antibacterials have been discovered. These include the oxazolidinones, glycolipopeptides, glycolipodepepsipe...

Descripción completa

Detalles Bibliográficos
Autores principales: Paknikar, Simi S, Narayana, Sarala
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3503371/
https://www.ncbi.nlm.nih.gov/pubmed/23181224
http://dx.doi.org/10.4103/1947-2714.103312
_version_ 1782250437966036992
author Paknikar, Simi S
Narayana, Sarala
author_facet Paknikar, Simi S
Narayana, Sarala
author_sort Paknikar, Simi S
collection PubMed
description In order to deal with the rising problem of antibiotic resistance, newer antibacterials are being discovered and added to existing pool. Since the year 2000, however, only four new classes of antibacterials have been discovered. These include the oxazolidinones, glycolipopeptides, glycolipodepepsipeptide and pleuromutilins. Newer drugs were added to existing classes of antibiotics, such as streptogramins, quinolones, beta-lactam antibiotics, and macrolide-, tetracycline- and trimethoprim-related drugs. Most of the antibacterials are directed against resistant S. aureus infections, with very few against resistant gram-negative infections. The following article reviews the antibacterials approved by the FDA after the year 2000 as well as some of those in clinical trials. Data was obtained through a literature search via Pubmed and google as well as a detailed search of our library database.
format Online
Article
Text
id pubmed-3503371
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Medknow Publications & Media Pvt Ltd
record_format MEDLINE/PubMed
spelling pubmed-35033712012-11-23 Newer Antibacterials in Therapy and Clinical Trials Paknikar, Simi S Narayana, Sarala N Am J Med Sci Review Article In order to deal with the rising problem of antibiotic resistance, newer antibacterials are being discovered and added to existing pool. Since the year 2000, however, only four new classes of antibacterials have been discovered. These include the oxazolidinones, glycolipopeptides, glycolipodepepsipeptide and pleuromutilins. Newer drugs were added to existing classes of antibiotics, such as streptogramins, quinolones, beta-lactam antibiotics, and macrolide-, tetracycline- and trimethoprim-related drugs. Most of the antibacterials are directed against resistant S. aureus infections, with very few against resistant gram-negative infections. The following article reviews the antibacterials approved by the FDA after the year 2000 as well as some of those in clinical trials. Data was obtained through a literature search via Pubmed and google as well as a detailed search of our library database. Medknow Publications & Media Pvt Ltd 2012-11 /pmc/articles/PMC3503371/ /pubmed/23181224 http://dx.doi.org/10.4103/1947-2714.103312 Text en Copyright: © North American Journal of Medical Sciences http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Paknikar, Simi S
Narayana, Sarala
Newer Antibacterials in Therapy and Clinical Trials
title Newer Antibacterials in Therapy and Clinical Trials
title_full Newer Antibacterials in Therapy and Clinical Trials
title_fullStr Newer Antibacterials in Therapy and Clinical Trials
title_full_unstemmed Newer Antibacterials in Therapy and Clinical Trials
title_short Newer Antibacterials in Therapy and Clinical Trials
title_sort newer antibacterials in therapy and clinical trials
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3503371/
https://www.ncbi.nlm.nih.gov/pubmed/23181224
http://dx.doi.org/10.4103/1947-2714.103312
work_keys_str_mv AT paknikarsimis newerantibacterialsintherapyandclinicaltrials
AT narayanasarala newerantibacterialsintherapyandclinicaltrials